antibodies for therapeutic and diagnostic applications
DESCRIPTION
InBio Ltd. ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS. Facts on InBio. Established in Tallinn, 1999 General business idea: to develop new effective and selective skin c a ncer therapeutics and diagnostics. - PowerPoint PPT PresentationTRANSCRIPT
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio LtdInBio Ltd..
ANTIBODIES FOR THERAPEUTIC AND
DIAGNOSTIC APPLICATIONS
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
Facts on InBio
• Established in Tallinn, 1999
• General business idea: to develop new effective and selective skin cancer therapeutics and diagnostics.
• The company was initiated by a group of scientists of National Institute of Chemical Physics and Biophysics and Karolinska Institute, Sweden
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
1999 2000 2001Turnover 10000 225000 190000
Profit before taxes
-2000 19000 8000
Equity 3300 3300 3300Employees 2 4 7
Financial results (EUR):
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
Background for product development
• Cancer is the second most common cause of death in the developed world
• The limits of usefulness are being approached for conventional therapies and further advances will require principally new approaches
• The foreseen products of our company are prototypes of new anti-cancer drugs that are characterised by:
– -high degree of selectivity – -efficient delivery
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
What is antibody?
• Antibodies are made by a class of white blood cells
• They are naturally present in the blood
• Biological function is to perform defence functions
• Each antigen causes the formation of a specific antibody
• Recombinant DNA technology allows the engineer antibodies
• It is possible to produce complete antibodies in cell culture systems.
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
Reasons to use antibodies in drug development
• Can be rationally designed and easily made
• Can be engineered to add fragmenmts that enhance their therapeutic potential
• Have no intrinsic toxicity as based on the natural molecules
• Monoclonal antibodies (mAbs)will not fail at the drug safety testing (phase I clinical trial stages)
• Technology is now advanced enough for therapeutic applications of mAbs
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
What is new in our technology?
• Our technology combines two different platforms:
• Monoclonal antibodies against cancer-specific antigens
– Modification of antibody sequence to make these mAbs membrane permeable
• Such approach helps to utilise intracellular cancer-specific targets that can not be usually reached
• Focus on skin cancer, first targets are GLI proteins
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
What are GLI proteins?
• GLI proteins are gene switches
• GLI proteins are involved in development and lead cells to divide
• Abnormal activation of GLI proteins lead to cancer
• GLI proteins represent an attractive target for anticancer drug development
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
Gene switch turned on Cancer develops
Cancer development inhibited
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
Cell penetrating peptides (CPPs)
• Family of peptides capable to penetrate cellular membranes
• We can transport the following molecules into cells using CPP technology:
• -other peptides
• -nucleic acids
• -proteins e.g. antibodies
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
World antibody market:
• Currently more than 200 monoclonal antibodies are in development
• Targeted disorders include cancer, heart disease, infectious diseases and autoimmune diseases
• Market is still in its inception stage,
• Market size estimated at nearly $2.8 billion in 1999,
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
World antibody market:
• Market forecast growth to almost $9.8 billion in 2004.
• Expected therapeutic antibody average annual growth rate is projected at 21,8%
• Diagnostic/therapeutic antibody AAGR will grow at fast nearly 50% rate
• Main Target Markets for InBio:
• Scandinavian Market
• U.S. market
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
Timing and positioning
• Antibody based drugs are in the position of significant commercial growth
• InBio enters the market at the moment when all developers seek for new approaches
• InBio has new technology to make antibodies more effective
• InBio has involved outstanding specialists from all fields that are required to accomplish our business plan
InBio LtdInBio Ltd..______________________________________________________________________
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
Benefits for the investor:
• Will invest in profitable business at evolving market
• Will invest in area that is significantly improving the well-being of the mankind
• Will get possession rights of a unique know-how and new technologies that will realise in new type of therapeutic and diagnostic tools